DOCSLIB.ORG

1 Supplemental Material Supplemental Table S1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Supplemental Material Supplemental Table S1 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Supplemental Material Supplemental Table S1. Psychotropic drugs investigated in the study ATC codes Drug names Antipsychotics (N05A) [excluding lithium (N05AN)] First-generation N05AA Chlorpromazine, Levomepromazine N05AB Perphenazine N05AD Haloperidol N05AL Sulpiride, Tiapride Not assigned Propericiazine Second-generation N05AH Olanzapine, Quetiapine N05AX Risperidone, Aripiprazole, Paliperidone Not assigned Blonanserin, Perospirone Antidepressants (N06A) Non-selective monoamine N06AA Imipramine, Clomipramine, Lofepramine, Amitriptyline, reuptake inhibitors Maprotiline Not assigned Setiptiline Selective serotonin reuptake N06AB Paroxetine, Sertraline, Fluvoxamine, Escitalopram inhibitors Others N06AX Mianserin, Trazodone, Mirtazapine, Milnacipran, Duloxetine Hypnotics and sedatives (N05C) Barbiturates N05CA Amobarbital N05CB Phenobarbital + Chlorpromazine + Promethazine Benzodiazepines N05CD Nitrazepam, Flunitrazepam, Estazolam, Triazolam, Lormetazepam, Brotizolam Not assigned Rilmazafone Benzodiazepine related N05CF Zopiclone, Zolpidem, Eszopiclone drugs (Z-drugs) Others N05CH Ramelteon N05CM Suvorexant Anxiolytics (N05B) Benzodiazepines N05BA Diazepam, Chlordiazepoxide, Medazepam, Potassium clorazepate, Lorazepam, Alprazolam, Fludiazepam, Ethyl loflazepate, Etizolam, Clotiazepam Not assigned Oxazolam Others Not assigned Tandospirone Antiepileptics (N03A) Antiepileptics N03AA Phenobarbital, Primidone N03AB Phenytoin N03AE Clonazepam N03AF Carbamazepine N03AG Valproic acid N03AX Lamotrigine, Levetiracetam, Zonisamide Lithium (N05AN) Lithium N05AN Lithium ATC, Anatomical Therapeutic Chemical Classification System The drug names listed were prescribed at least once in the study cohort. Prochlorperazine (N05AB), hydroxyzine (N05BB), and pregabalin (N03AX) were not included in this study because these drugs were predominantly used for other indications in Japan. 1 Hamada S, et al. BMJ Open 2021; 11:e045787. doi: 10.1136/bmjopen-2020-045787 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Supplemental Table S2. Drugs with anticholinergic properties investigated in the study Category Class & Drug substance Extended list (National guidance) (National guidance, ARS, Beers criteria) Antidepressants Tricyclic antidepressants (all) + Mirtazapine e.g. Imipramine, Clomipramine, + Trazodone Amitriptyline Paroxetine Antipsychotics Phenothiazine antipsychotics (all) + Haloperidol e.g. Chlorpromazine, Levomepromazine + Quetiapine Olanzapine, Clozapine + Risperidone Drugs for Parkinson’s Trihexyphenidyl + Amantadine disease Biperiden + Carbidopa-levodopa + Entacapone + Pramipexole + Selegiline Antiarrhythmic drugs Disopyramide – Skeletal muscle Tizanidine + Baclofen relaxants + Methocarbamol + Pancuronium + Thioridazine Drugs for overactive Muscarinic receptor antagonists (all) + Flavoxate bladder e.g. Oxybutynin, Propiverine, Solifenacin Antispasmodic drugs Antispasmodic drugs (all) – e.g. Atropine, Scopolamine butylbromide Antiemetics Prochlorperazine – Metoclopramide Histamine H2-receptor Histamine H2-receptor antagonists (all) – antagonists e.g. Cimetidine, Ranitidine Histamine H1-receptor First-generation histamine H1-receptor + Cetirizine antagonists antagonists (all) + Loratadine e.g. Chlorpheniramine, Diphenhydramine Others – + Dimenhydrinate + Loperamide + Trospium ARS, Anticholinergic Risk Scale 2 Hamada S, et al. BMJ Open 2021; 11:e045787. doi: 10.1136/bmjopen-2020-045787 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Supplemental Table S3. Characteristics of residents with disabling dementia at admission according to dementia severity Dementia severity Overall Moderate Severe P value (n = 1,057) (n = 498) (n = 559) Age (years) 65–74 79 (7.5) 36 (7.2) 43 (7.7) 0.773 75–84 329 (31.1) 157 (31.5) 172 (30.8) 85–94 544 (51.5) 251 (50.4) 293 (52.4) 95+ 105 (9.9) 54 (10.8) 51 (9.1) Mean ± SD 86 ± 7 86 ± 7 86 ± 7 0.847 Sex Men 262 (24.8) 114 (22.9) 148 (26.5) 0.178 Women 795 (75.2) 384 (77.1) 411 (73.5) Physical disability Non-bedridden 336 (31.8) 212 (42.6) 124 (22.2) <0.001 Bedridden 721 (68.2) 286 (57.4) 435 (77.8) SD, standard deviation 3 Hamada S, et al. BMJ Open 2021; 11:e045787. doi: 10.1136/bmjopen-2020-045787 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Supplemental Table S4. Utilisation of antidementia drugs, psychotropic drugs and drugs with anticholinergic properties according to dementia severity Dementia severity Mild-to-moderate Moderate-to-severe Moderate Severe Discontinu Discontinu Discontinu Discontinu Admission Month 2 -ation Admission Month 2 -ation Admission Month 2 -ation Admission Month 2 -ation n (% of n (% of n (% of n (% of n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) users at users at users at users at admission)† admission)† admission)† admission)† Antidementia drugs 100 (15.6) 76 (11.8) 28 (28.0) 223 (21.1) 149 (14.1) 80 (35.9) 90 (18.1) 69 (13.9) 24 (26.7) 133 (23.8) 80 (14.3) 56 (42.1) Psychotropic drugs 281 (43.8) 255 (39.7) 65 (23.1) 465 (44.0) 456 (43.1) 96 (20.6) 214 (43.0) 197 (39.6) 48 (22.4) 251 (44.9) 259 (46.3) 48 (19.1) Hypnotics 172 (26.8) 150 (23.4) 31 (18.0) 254 (24.0) 236 (22.3) 47 (18.5) 125 (25.1) 114 (22.9) 20 (16.0) 129 (23.1) 121 (21.6) 27 (20.9) Antipsychotics 57 (8.9) 53 (8.3) 11 (19.3) 148 (14.0) 154 (14.6) 28 (18.9) 47 (9.4) 44 (8.8) 9 (19.1) 101 (18.1) 112 (20.0) 19 (18.8) Anxiolytics 93 (14.5) 78 (12.1) 20 (21.5) 125 (11.8) 108 (10.2) 30 (24.0) 70 (14.1) 58 (11.6) 17 (24.3) 55 (9.8) 50 (8.9) 13 (23.6) Antidepressants 49 (7.6) 43 (6.7) 9 (18.4) 79 (7.5) 71 (6.7) 13 (16.5) 39 (7.8) 33 (6.6) 7 (17.9) 40 (7.2) 38 (6.8) 6 (15.0) Antiepileptic drugs 40 (6.2) 40 (6.2) 2 (5.0) 75 (7.1) 84 (7.9) 3 (4.0) 30 (6.0) 30 (6.0) 1 (3.3) 45 (8.1) 54 (9.7) 2 (4.4) Lithium 2 (0.3) 2 (0.3) 0 (0.0) 1 (0.1) 1 (0.1) 0 (0.0) 1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Drugs with anticholinergic 204 (31.8) 217 (33.8) 38 (18.6) 378 (35.8) 395 (37.4) 68 (18.0) 159 (31.9) 172 (34.5) 29 (18.2) 219 (39.2) 223 (39.9) 39 (17.8) properties Frequently prescribed drugs‡ H2-receptor antagonists 88 (13.7) 105 (16.4) 11 (12.5) 146 (13.8) 171 (16.2) 19 (13.0) 72 (14.5) 85 (17.1) 10 (13.9) 74 (13.2) 86 (15.4) 9 (12.2) Antipsychotics 38 (5.9) 36 (5.6) 8 (21.1) 99 (9.4) 106 (10.0) 22 (22.2) 31 (6.2) 29 (5.8) 7 (22.6) 68 (12.2) 77 (13.8) 15 (22.1) Drugs for overactive bladder 37 (5.8) 39 (6.1) 5 (13.5) 61 (5.8) 60 (5.7) 11 (18.0) 25 (5.0) 30 (6.0) 2 (8.0) 36 (6.4) 30 (5.4) 9 (25.0) Drugs for Parkinson’s 24 (3.7) 25 (3.9) 3 (12.5) 48 (4.5) 47 (4.4) 6 (12.5) 16 (3.2) 18 (3.6) 2 (12.5) 32 (5.7) 29 (5.2) 4 (12.5) disease Antidepressants 23 (3.6) 23 (3.6) 4 (17.4) 48 (4.5) 46 (4.4) 7 (14.6) 16 (3.2) 14 (2.8) 3 (18.8) 32 (5.7) 32 (5.7) 4 (12.5) †Discontinuation of psychotropic drugs (PD) or drugs with anticholinergic properties (DAP) overall was defined as a decrease in the number of drug categories from PD or DAP, from admission to month 2, respectively. ‡See online supplemental table S2 for specific drugs included in each drug category. 4 Hamada S, et al. BMJ Open 2021; 11:e045787. doi: 10.1136/bmjopen-2020-045787 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Supplemental Table S5. Associations of residents’ characteristics at admission with the prescriptions 2 months after admission in residents with disabling dementia Age, ≥85 years Women Severe dementia Bedridden Factors (ref. 65–84) (ref. men) (ref. moderate) (ref. not bedridden) aOR (95% CI) P value aOR (95% CI) P value aOR (95% CI) P value aOR (95% CI) P value Antidementia drugs 0.90 (0.62 to 1.30) 0.567 1.56 (0.99 to 2.47) 0.054 1.28 (0.89 to 1.84) 0.183 0.42 (0.29 to 0.60) <0.001 Antipsychotics 0.63 (0.44 to 0.90) 0.012 1.31 (0.86 to 2.00) 0.212 3.09 (2.09 to 4.57) <0.001 0.61 (0.42 to 0.89) 0.010 First-generation 0.58 (0.34 to 0.96) 0.035 1.31 (0.71 to 2.42) 0.383 2.56 (1.46 to 4.49) 0.001 0.66 (0.38 to 1.13) 0.126 Second-generation 0.65 (0.42 to 0.99) 0.047 1.26 (0.76 to 2.09) 0.369 2.79 (1.75 to 4.46) <0.001 0.62 (0.39 to 0.96) 0.034 Hypnotics 0.74 (0.54 to 0.99) 0.046 0.83 (0.60 to 1.17) 0.288 0.96 (0.71 to 1.29) 0.778 0.80 (0.58 to 1.09) 0.153 Anxiolytics 0.59 (0.39 to 0.89) 0.011 1.33 (0.81 to 2.17) 0.260 0.75 (0.50 to 1.12) 0.162 1.04 (0.67 to 1.61) 0.870 Antidepressants 0.48 (0.29 to 0.78) 0.003 1.15 (0.65 to 2.03) 0.633 1.09 (0.66 to 1.79) 0.738 0.77 (0.46 to 1.29) 0.325 Antiepileptic drugs 0.23 (0.14 to 0.38) <0.001 0.82 (0.50 to 1.34) 0.424 1.60 (0.99 to 2.59) 0.055 1.47 (0.85 to 2.54) 0.167 Drugs with anticholinergic properties 0.68 (0.52 to 0.88) 0.003 0.95 (0.71 to 1.28) 0.756 1.27 (0.98 to 1.64) 0.070 0.96 (0.73 to 1.27) 0.796 Factors associated with prescribing of lithium could not be evaluated because of the small number of participants who had been prescribed this drug.
Load more

Recommended publications
  • Uso Adecuado De BZD En Insomnio Y Ansiedad.Pdf
    Vol. 6 Nº 1 · OCTUBRE 2014 BOLETÍN CANARIO DE USO RACIONAL DEL MEDICAMENTO DEL SCS Uso adecuado de BENZODIAZEPINAS en insomnio y ansiedad. SUMARIO PERFIL FARMACOLÓGICO DE LAS BZD (Tabla 1). - INTRODUCCIÓN 1 - PERFIL FARMACOLÓGICO DE LAS BENZODIAZEPINAS 1 No todas las BZD son iguales, ni tienen las mismas indicaciones. - BENZODIAZEPINAS EN EL INSOMNIO 2 Conocer algunos aspectos sobre su perfil farmacológico es esencial para realizar una prescripción adecuada y segura. - BENZODIAZEPINAS EN LA ANSIEDAD 4 - RECOMENDACIONES PARA SUSPENDER 5 Por lo general las BZD se absorben muy bien por vía oral, mientras TRATAMIENTOS CON BZD que la vía intramuscular presenta una absorción lenta e irregular, por - BIBLIOGRAFÍA 7 lo que no suele ser muy recomendada. En situaciones de emergencia (convulsiones) es preferible utilizar la vía endovenosa. INTRODUCCIÓN Inicio de acción y vida media: el inicio de acción es distinto según el principio activo y constituye un criterio fundamental en la selección de Las benzodiazepinas (BZD) son psicofármacos que actúan aumentan- las BZD. Puede ser: de inicio rápido (0,5-1 h), de utilidad en el insomnio do la acción del ácido gammaaminobutírico (GABA), principal neuro- de conciliación y en crisis de ansiedad; de inicio intermedio (1-3 h) o transmisor inhibidor del sistema nervioso central. Tienen indicaciones de inicio lento (> 3 h), preferibles en insomnio de mantenimiento o terapéuticas diversas, y auque su uso más habitual es en el tratamien- despertar precoz y en la ansiedad generalizada. to de la ansiedad e insomnio, también se utilizan en la inducción a la anestesia, en el tratamiento de las crisis comiciales, en el síndrome La vida media de las BZD es otro de los criterios de selección y puede 5 de abstinencia alcohólica, como tratamiento coadyuvante de de dolor ser : corta (< 6 h); intermedia (6-24 h) y larga (> 24 h).
    [Show full text]
  • Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam
    Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam Tjiauw-Ling Tan, MD, Edward 0. Bixler, PhD, Anthony Kales, MD, Roger J. Cadieux, MD, and Amy L. Goodman, MD Hershey, Pennsylvania A psychiatric syndrome characterized by agita­ Sleep Disorders Clinic. He began taking triazolam tion, paranoid ideation, depersonalization, and de­ at bedtime in a 0.5-mg dose eight months before pression, as well as paresthesias and hyperacusis, his referral. Although the drug was effective ini­ has been attributed to administration of triazolam tially, tolerance developed, causing the patient to (Halcion).1 The occurrence of these reactions led gradually increase the dosage until eventually he to the removal of the drug from the market in the was taking a total of 1.5 mg nightly. Netherlands. Isolated behavioral side effects that The physical examination revealed no contribu­ include amnesia2-4 and hallucinations5 have also tory conditions. However, assessment of the pa­ been reported with administration of triazolam. tient’s mental status revealed that he was extreme­ Rebound insomnia6 and early morning insom­ ly guarded and suspicious and preoccupied with nia,7 both associated with increases in daytime his sleeplessness to the degree that this hypochon­ anxiety,7,8 are withdrawal syndromes known driacal concern had a delusional quality. He also to occur with rapidly eliminated benzodiazepine described two episodes indicating memory impair­ hypnotics such as triazolam. Rebound insomnia ment; both incidents occurred in the late afternoon consists of a marked increase in wakefulness and involved preparing to eat certain foods, which above baseline levels following drug withdrawal.
    [Show full text]
  • Withdrawing Benzodiazepines in Primary Care
    PC\/ICU/ ADTiriC • CNS Drugs 2009,-23(1): 19-34 KtVltW MKIIWLC 1172-7047/I»/O(X)1«119/S4W5/C1 © 2009 Adis Dato Intocmation BV. All rights reserved. Withdrawing Benzodiazepines in Primary Care Malcolm Luder} Andre Tylee^ and ]ohn Donoghue^ 1 Institute of Psychiatry, King's College London, London, England 2 John Moores University, Liverpool, Scotland Contents Abstract ' 19 1. Benzodiazepine Usage 22 2. Interventions 23 2.1 Simple interventions 23 2.2 Piiarmacoiogicai interventions 25 2.3 Psychoiogical Interventions 26 2.4 Meta-Anaiysis ot Various interventions 27 3. Outcomes 28 4. Practicai Issues 29 5. Otiier Medications 30 5.1 Antidepressants 30 5.2 Symptomatic Treatments 30 6. Conciusions 31 Abstract The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinua- tion is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addic- tion have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescdbers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discon- tinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescdbers.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • Residual Effects of Sleep Medication on Driving Ability
    Sleep Medicine Reviews (2004) 8, 309–325 www.elsevier.com/locate/smrv CLINICAL REVIEW Residual effects of sleep medication on driving ability Joris C. Verster*, Dieuwke S. Veldhuijzen, Edmund R. Volkerts Department of Psychopharmacology, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, PO Box 80082, 3508 TB, Utrecht, The Netherlands KEYWORDS Summary Most patients using hypnotics are ambulatory and presumably have a job and Zaleplon; Zolpidem; drive a car. Since driving a car is one of the most common but potentially dangerous Zopiclone; daily activities, hypnotics should act rapidly when needed, but daytime sleepiness and Benzodiazepine; other residual effects that may impair performance are unwanted. This review Hypnotics; Insomnia; summarizes the effects of hypnotics on driving ability as determined with the on-the- Driving; Sedation road driving test during normal traffic. Supportive evidence from epidemiological data, and results from driving simulators and closed-road studies are also considered. On-the-road studies revealed that benzodiazepine hypnotics significantly impaired driving ability the morning following bedtime administration. Impairment was sometimes also significant in the afternoon (16–17 h after administration). Similar driving impairment was observed with zopiclone. However, the magnitude of impairment depends on various factors including the half-life and dosage of the drug, and the time after administration. The results from on-the-road driving studies are supported by evidence obtained in driving simulators and laboratory tests. Epidemiological data and on-the-road studies show that tolerance develops to the impairing effects of hypnotics. However, this is a slow process, and impairment may persist. Patients treated with benzodiazepine hypnotics or zopiclone should be cautioned when driving a car.
    [Show full text]
  • Risk of Recurrent Overdose Associated with Prescribing Patterns of Psychotropic Medications After Nonfatal Overdose
    Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Year: 2017 Volume: 13 Neuropsychiatric Disease and Treatment Dovepress Running head verso: Okumura and Nishi Running head recto: Risk of recurrent overdose with benzodiazepines open access to scientific and medical research DOI: http://dx.doi.org/10.2147/NDT.S128278 Open Access Full Text Article ORIGINAL RESEARCH Risk of recurrent overdose associated with prescribing patterns of psychotropic medications after nonfatal overdose Yasuyuki Okumura1 Objective: We aimed to estimate risk of recurrent overdose associated with psychosocial Daisuke Nishi2 assessment by psychiatrists during hospitalization for nonfatal overdose and prescribing patterns of psychotropic medications after discharge. 1Research Department, Institute for Health Economics and Policy, Methods: A retrospective cohort study was conducted using a nationwide claims database Association for Health Economics in Japan. We classified patients aged 19–64 years hospitalized for nonfatal overdose between Research and Social Insurance and Welfare, Tokyo, 2Department of October 2012 and September 2013 into two cohorts: 1) those who had consulted a psychiatrist Mental Health Policy and Evaluation, prior to overdose (n=6,790) and 2) those who had not (n=4,950). All patients were followed up National Institute of Mental Health, from 90 days before overdose until 365 days after discharge. National Center of Neurology and Psychiatry, Kodaira, Japan Results: Overall, 15.3% of patients with recent psychiatric treatment had a recurrent overdose within 365 days, compared with 6.0% of those without psychiatric treatment. Psychosocial For personal use only. assessment during hospital admission had no significant effect on subsequent overdose, irrespec- tive of treatment by psychiatrists before overdose.
    [Show full text]
  • Treatment Response in Depressed Patients with Enhanced Ca Mobilization Stimulated by Serotonin
    Title Treatment response in depressed patients with enhanced Ca mobilization stimulated by serotonin Author(s) Kusumi, Ichiro; Suzuki, Katsuji; Sasaki, Yuki; Kameda, Kensuke; Koyama, Tsukasa Neuropsychopharmacology, 23(6), 690-696 Citation https://doi.org/10.1038/sj.npp.1395557 Issue Date 2000-12 Doc URL http://hdl.handle.net/2115/8436 Type article (author version) File Information NPP.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP revised to Neuropsychopharmacology Treatment response in depressed patients with enhanced Ca mobilization stimulated by serotonin Ichiro Kusumi, M.D., Ph.D., Katsuji Suzuki, M.D., Yuki Sasaki, B.Sc., Kensuke Kameda, M.D.,Ph.D., and Tsukasa Koyama, M.D., Ph.D. Department of Psychiatry, Hokkaido University School of Medicine North 15, West 7, Sapporo 060-8638, Japan Running title: Treatment response and Ca mobilization Correspondence: Ichiro Kusumi, M.D., Ph.D. TEL: +81-11-716-1161 ext.5973 FAX: +81-11-736-0956 e-mail: [email protected] 1 ABSTRACTS Serotonin (5-HT)-stimulated intraplatelet calcium (Ca) mobilization has been shown to be enhanced in nonmedicated depressive patients by many studies. However, there has not been any longitudinal follow-up study of this parameter. We examined the relationship between treatment response and pretreatment value of the 5-HT-induced Ca response. The 5-HT(10 uM)- induced intraplatelet Ca mobilization was measured in 98 nonmedicated depressive patients (24 bipolar disorders, 51 melancholic major depressive disorder and 23 non-melancholic major depressive disorder). These patients were followed up prospectively for a further period of 5 years. The depressed patients with enhanced Ca response to 5-HT in bipolar disorders exhibited a good response to mood stabilizers but those in major depressive disorders showed a poor response to antidepressants.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Calculating Equivalent Doses of Oral Benzodiazepines
    Calculating equivalent doses of oral benzodiazepines Background Benzodiazepines are the most commonly used anxiolytics and hypnotics (1). There are major differences in potency between different benzodiazepines and this difference in potency is important when switching from one benzodiazepine to another (2). Benzodiazepines also differ markedly in the speed in which they are metabolised and eliminated. With repeated daily dosing accumulation occurs and high concentrations can build up in the body (mainly in fatty tissues) (2). The degree of sedation that they induce also varies, making it difficult to determine exact equivalents (3). Answer Advice on benzodiazepine conversion NB: Before using Table 1, read the notes below and the Limitations statement at the end of this document. Switching benzodiazepines may be advantageous for a variety of reasons, e.g. to a drug with a different half-life pre-discontinuation (4) or in the event of non-availability of a specific benzodiazepine. With relatively short-acting benzodiazepines such as alprazolam and lorazepam, it is not possible to achieve a smooth decline in blood and tissue concentrations during benzodiazepine withdrawal. These drugs are eliminated fairly rapidly with the result that concentrations fluctuate with peaks and troughs between each dose. It is necessary to take the tablets several times a day and many people experience a "mini-withdrawal", sometimes a craving, between each dose. For people withdrawing from these potent, short-acting drugs it has been advised that they switch to an equivalent dose of a benzodiazepine with a long half life such as diazepam (5). Diazepam is available as 2mg tablets which can be halved to give 1mg doses.
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • Benzodiazepines Factsheet
    Benzodiazepines This factsheet gives information about benzodiazepine medication. This medication is sometimes used to treat anxiety. Your doctor may prescribe this medication if your anxiety has become severe or if you are very distressed. Benzodiazepines are a type of medication that are used to treat anxiety. You may get side effects from taking this kind of medication. If you get side effects that you are worried about, you should see your doctor. You can become addicted to benzodiazepines. Therefore, you should not take them for longer than one month. You may get withdrawal symptoms when you stop taking benzodiazepines. You should talk to your doctor before you stop taking them. Your doctor may gradually take you off your medication if you have been taking them for a long time. This factsheet covers: 1. What are benzodiazepines? 2. Are there different types of benzodiazepines? 3. Are there any side effects? 4. What if I want to I stop taking benzodiazepines? 5. Do benzodiazepines affect other medication? 6. Does alcohol affect my benzodiazepines? 7. Can I drive when taking benzodiazepines? 8. What else should I consider before taking benzodiazepines? 1 1. What are benzodiazepines? Your doctor may offer you benzodiazepines if you have symptoms of anxiety which are causing you a lot of distress or if you are having difficulty sleeping. Benzodiazepines are a type of sedative and are mostly used as short-term treatment. They work by making the calming chemicals released by your body more powerful. You should not take benzodiazepines for longer than one month. If you take them for longer, you can become tolerant to them (meaning you need more to have the same effect), and you may also become dependent (addicted) to them.
    [Show full text]